While Human Immunodeficiency Virus (HIV) may not be as
common as cancer or heart disease, it is still a very serious disease that
affects millions. Roughly 36.7 million people around the world are living with HIV
according to the World Health Organization. There were 2.1 million newly
developed cases in 2015 alone and over one million died from HIV-related issues
that year. Fortunately, researchers are one step closer to an HIV vaccine.
An antibody, titled N6, discovered in an HIV-positive
patient was found to be able to neutralize 98% of all HIV strains that were
tested. Some of these strains were even resistant to similar antibodies. This
antibody could recognize HIV after it morphed and broke away from the antibody.
The evolution of this antibody was
monitored to see how it would react to the changing HIV virus. It was found
that the antibody relies more on binding to the parts of the virus that don’t
change much as opposed to the parts of the virus that do. HIV-positive people
are so susceptible to AIDS and infections because the HIV virus destroys their
immune cells. N6 prevents the virus from becoming attached to the host’s immune
cells and thus prevents HIV from attacking the cells.
This research has only been performed in the lab and not on
human subjects. So, we’re still a ways from an actual vaccine, but this research
gives hope that one day there will be
one.
Further Readings:
http://www.cell.com/immunity/abstract/S1074-7613(16)30438-1
But a vaccine isn't an antibody. Is the antibody supposed to be prophylactic against HIV and if so, by what mechanism?
ReplyDeleteThey intend for it to be used for therapy, vaccines, and prophylaxis. I didn't see anything about the exact mechanism, but it was a 35 page paper, so I honestly might have missed it. However, they did say that the potency of N6 might increase its durability as a prophylactic and that its breadth could limit the likelihood of transmission when used in prophylaxis.
Delete